Ilan Zipkin
Vorstandsvorsitzender bei Anteris Bio, Inc.
Profil
Ilan Zipkin is currently the Chief Executive Officer at Tempero Bio, Inc., and the President & Chief Executive Officer at Anteris Bio, Inc. He is also a Director at Via Nova Therapeutics, Inc. Previously, he was the Co-Chief Executive Officer at Versanis Bio, Inc., and held Director positions at Satori Pharmaceuticals, Inc., Chimeros, Inc., Alvine Pharmaceuticals, Inc., and Bioniz Therapeutics, Inc. He was also a Senior Investment Director at Takeda Ventures, Inc. from 2000 to 2017.
Dr. Zipkin has a doctorate degree from The University of California, San Francisco, and an undergraduate degree from the University of California, Berkeley.
Aktive Positionen von Ilan Zipkin
| Unternehmen | Position | Beginn |
|---|---|---|
Via Nova Therapeutics, Inc.
 Via Nova Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Via Nova Therapeutics, Inc. is a company that aims to discover and develop safe and effective therapies for viral diseases with inadequate treatments. The company is based in Oakland, CA. Via Nova's pipeline includes four programs targeting influenza, human rhinovirus, polyomavirus, and adenovirus. The company is committed to advancing this initial pipeline with additional discovery efforts to follow. Via Nova believes that the recent expansion of point-of-care testing and telemedicine driven by the COVID-19 pandemic will transform the diagnostic landscape, allowing early recognition of all the important respiratory viruses. The company was founded in August 2021 and has in-licensed antiviral programs from RTIs. The CEO of the company is Donald Emil Ganem. | Direktor/Vorstandsmitglied | - |
Tempero Bio, Inc.
 Tempero Bio, Inc. Pharmaceuticals: MajorHealth Technology Tempero Bio, Inc. engages in clinical development of mGlu5 NAM program in neurological diseases. The company is headquartered in Oakland, CA. | Vorstandsvorsitzender | - |
Anteris Bio, Inc.
 Anteris Bio, Inc. Pharmaceuticals: MajorHealth Technology Anteris Bio, Inc. develops therapies for the treatment of renal disease. The company is based in Oakland, CA. The CEO of the company is Ilan Zipkin. | Vorstandsvorsitzender | - |
Ehemalige bekannte Positionen von Ilan Zipkin
| Unternehmen | Position | Ende |
|---|---|---|
Takeda Ventures, Inc.
 Takeda Ventures, Inc. Investment ManagersFinance Takeda Ventures Inc (Takeda Ventures) is a venture capital subsidiary of Takeda America Holdings Inc founded in 2001. The firm is headquartered in Palo Alto, California. | Private Equity Investor | 01.06.2017 |
Chimeros, Inc.
 Chimeros, Inc. Pharmaceuticals: MajorHealth Technology Chimeros, Inc. develops novel therapies for cancer treatment. It focuses on the development of novel targeted treatments while generating immediate revenues from licensing platform rights and development contracts. Chimeros was founded in 2004 and is headquartered in San Diego, CA. | Direktor/Vorstandsmitglied | 09.01.2014 |
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | 01.06.2005 |
Versanis Bio, Inc.
 Versanis Bio, Inc. BiotechnologyHealth Technology Part of Eli Lilly & Co., Versanis Bio, Inc. is a clinical-stage biopharmaceutical company. The company is based in New York, NY. The company was founded by Lloyd Klickstein. Mark E. Pruzanski has been the CEO of the company since 2021. Versanis Bio was acquired by Eli Lilly & Co. on August 14, 2023 for $1,925 million. | Vorstandsvorsitzender | - |
| QUINCE THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | - |
Ausbildung von Ilan Zipkin
| University of California, Berkeley | Undergraduate Degree |
| The University of California, San Francisco | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| QUINCE THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 11 |
|---|---|
Satori Pharmaceuticals, Inc.
 Satori Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Satori Pharmaceuticals, Inc. developed therapeutics for alzheimer's disease. The firm's drug candidates selectively modulated gamma secretase, the enzyme generating the neurotoxic peptides that form amyloid beta plaques the signature of this debilitated disease. The company was founded by Mark A. Findeis and Dennis J. Selkoe in 2005 and was headquartered in Cambridge, MA. | Health Technology |
Chimeros, Inc.
Chimeros, Inc. Pharmaceuticals: MajorHealth Technology Chimeros, Inc. develops novel therapies for cancer treatment. It focuses on the development of novel targeted treatments while generating immediate revenues from licensing platform rights and development contracts. Chimeros was founded in 2004 and is headquartered in San Diego, CA. | Health Technology |
Alvine Pharmaceuticals, Inc.
 Alvine Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Alvine Pharmaceuticals, Inc. develops and commercializes therapeutics for inflammatory diseases. It offers ALV003, tTG Inihibitors and HLA-DQ2 Blockers. The company was founded by Blair Stewart and Kevin R. Kaster in 2005 and is headquartered in San Carlos, CA. | Health Technology |
Bioniz Therapeutics, Inc.
 Bioniz Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Bioniz Therapeutics, Inc. operates as a biopharmaceutical firm. The firm engages in the development of peptide therapeutics that selectively and simultaneously inhibit multiple cytokines for the treatment of immune diseases and cancer. The company was founded by Yutaka Tagaya and Nazli Azimi in 2009 and is headquartered in Irvine, CA. | Commercial Services |
MPM BioImpact, Inc
MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Finance |
Prospect Venture Partners
 Prospect Venture Partners Investment ManagersFinance Prospect Venture Partners (Prospect Venture Partners) is a venture capital firm founded in 1997 by Alexander E. Barkas and David Schnell. The firm is headquartered in Palo Alto, California. | Finance |
Takeda Ventures, Inc.
Takeda Ventures, Inc. Investment ManagersFinance Takeda Ventures Inc (Takeda Ventures) is a venture capital subsidiary of Takeda America Holdings Inc founded in 2001. The firm is headquartered in Palo Alto, California. | Finance |
Tempero Bio, Inc.
Tempero Bio, Inc. Pharmaceuticals: MajorHealth Technology Tempero Bio, Inc. engages in clinical development of mGlu5 NAM program in neurological diseases. The company is headquartered in Oakland, CA. | Health Technology |
Versanis Bio, Inc.
Versanis Bio, Inc. BiotechnologyHealth Technology Part of Eli Lilly & Co., Versanis Bio, Inc. is a clinical-stage biopharmaceutical company. The company is based in New York, NY. The company was founded by Lloyd Klickstein. Mark E. Pruzanski has been the CEO of the company since 2021. Versanis Bio was acquired by Eli Lilly & Co. on August 14, 2023 for $1,925 million. | Health Technology |
Via Nova Therapeutics, Inc.
Via Nova Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Via Nova Therapeutics, Inc. is a company that aims to discover and develop safe and effective therapies for viral diseases with inadequate treatments. The company is based in Oakland, CA. Via Nova's pipeline includes four programs targeting influenza, human rhinovirus, polyomavirus, and adenovirus. The company is committed to advancing this initial pipeline with additional discovery efforts to follow. Via Nova believes that the recent expansion of point-of-care testing and telemedicine driven by the COVID-19 pandemic will transform the diagnostic landscape, allowing early recognition of all the important respiratory viruses. The company was founded in August 2021 and has in-licensed antiviral programs from RTIs. The CEO of the company is Donald Emil Ganem. | Health Technology |
Anteris Bio, Inc.
Anteris Bio, Inc. Pharmaceuticals: MajorHealth Technology Anteris Bio, Inc. develops therapies for the treatment of renal disease. The company is based in Oakland, CA. The CEO of the company is Ilan Zipkin. | Health Technology |
